• Alex Vorsters, F Xavier Bosch, Mario Poljak, Dur-E-Nayab Waheed, Margaret Stanley, Suzanne M Garland, and HPV Prevention and Control Board and the International Papillomavirus Society (IPVS).
• Center for the Evaluation of Vaccination & HPV Prevention and Control Board, University of Antwerp, Antwerp, Belgium. Electronic address: alex.vorsters@uantwerpen.be.
• Prev Med. 2022 Mar 1; 156: 106960106960.

AbstractThe global confrontation with COVID-19 has not only diverted current healthcare resources to deal with the infection but has also resulted in increased resources in the areas of testing and screening, as well as educating most of the global public of the benefits of vaccination. When the COVID-19 pandemic eventually recedes, the opportunity must not be missed to ensure that these newly created resources are maintained and redeployed for use in testing and immunisation against other vaccine-preventable infectious diseases. A notable example is infection by human papillomavirus (HPV), the commonest sexually transmitted human virus and the leading cause of a variety of cancers in both men and women, such as cervical, head and neck, anal, vaginal, vulvar and penile cancers. The most important is cervical cancer, the objective of the global elimination goals targeting the vaccination of young female and male adolescents, screening all women and treatment of all infected women. As the campaigns to control SARS-CoV-2, the eradication of HPV-induced cancers also relies on effective prevention and control programs. The lessons learned and the technical, logistical and human resources which have been established to combat COVID-19 by vaccination and testing must be applied to the eradication of other infections which affect the global population. This commentary summarizes the opportunities that the COVID-19 pandemic has created for HPV prevention and control, lists the already available tools for HPV control, and emphasizes the potential public health threats amidst the ongoing COVID-19 pandemic.Copyright © 2022 Elsevier Inc. All rights reserved.

26 keywords...

hide…